FUNDAMENTALS |
MarketCap: |
39 699 mill
|
EPS: |
10.08
|
P/E: |
47.40
|
Earnings Date: |
May 01, 2024 |
SharesOutstanding: |
83.09 mill
|
Avg Daily Volume: |
0.411 mill
|
RATING
2024-04-18 |
S
|
Strong Buy
|
RATINGS |
Rating CashFlow: |
Buy
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Strong Buy
|
|
DE: |
Strong Buy
|
|
P/E: |
Strong Buy
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE 47.40 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
2.53x
|
Company: PE 47.40 | industry: PE 18.71
|
DISCOUNTED CASH FLOW VALUE |
$155.32
(-67.49%)
$-322.47
|
Date: 2024-04-19
|
Expected Trading Range (DAY) |
$ 466.74 - 488.84
( +/- 2.31%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-03-06 | Polewaczyk James F | Buy | 4 640 | Common Stock |
2024-03-06 | Polewaczyk James F | Sell | 4 134 | Common Stock |
2024-03-06 | Polewaczyk James F | Buy | 2 226 | Common Stock |
2024-03-06 | Polewaczyk James F | Buy | 483 | Common Stock |
2024-03-06 | Polewaczyk James F | Buy | 755 | Common Stock |
INSIDER POWER |
37.69
|
Last
100 transactions |
Buy:
74 111 | Sell:
33 078 |
Forecast:
16:00 - $477.20
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $477.20
Forecast 2: 16:00 - $477.20
Forecast 3: 16:00 - $477.20
SCORE
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$477.79 (-0.09% )
|
Volume |
0.375 mill
|
Avg. Vol. |
0.411 mill
|
% of Avg. Vol |
91.28 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For IDXX
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date |
Signal |
@ |
Closed |
% |
Feb 8 - 15:35 | sell | $573.47 | N/A | Active |
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.